PuSH - Publication Server of Helmholtz Zentrum München

28 Records found.
Zum Exportieren der Ergebnisse bitte einloggen.
Lay all publications on this page into basket
1.
Huber, K. et al.: Multimodal analysis of formalin-fixed and paraffin-embedded tissue by MALDI imaging and fluorescence in situ hybridization for combined genetic and metabolic analysis. Lab. Invest., accepted (2019)
2.
Haffner, I.* et al.: Determination of HER2 in Gastric Cancer (GC) is still challenging: high deviation rates between local and central pathologies and its impact on survival. Oncol. Res. Treat. 41, 240-240 (2018)
3.
Keller, S.* et al.: Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines. Mol. Oncol. 12, 441-462 (2018)
4.
Keller, S.* et al.: Evaluation of epidermal growth factor receptor signaling effects in gastric cancer cell lines by detailed motility-focused phenotypic characterization linked with molecular analysis. BMC Cancer 17:845 (2017)
5.
Kunzke, T. et al.: Native glycan fragments detected by MALDI-FT-ICR mass spectrometry imaging impact gastric cancer biology and patient outcome. Oncotarget 8, 68012-68025 (2017)
6.
Urban, C. et al.: PAXgene fixation enables comprehensive metabolomic and proteomic analyses of tissue specimens by MALDI MSI. Biochim. Biophys. Acta 1862, 51-60 (2017)
7.
Haffner, I.* et al.: Clinical validation of response and resistance factor candidates to targeted therapy in Gastric Cancer (GC). Oncol. Res. Treat. 39, 16-17 (2016)
8.
Luber, B.* et al.: Identification of predictive response and resistance factors to targeted therapy in gastric cancer using a systems medicine approach. Eur. J. Cancer 68, S135-S135 (2016)
9.
Aichler, M. et al.: Epidermal Growth Factor Receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget 5, 6620-6632 (2014)
10.
Aichler, M. ; Luber, B.* ; Lordick, F.* & Walch, A.K.: Proteomic and metabolic prediction of response to therapy in gastric cancer. World J. Gastroenterol. 20, 13648-13657 (2014)
11.
Feuchtinger, A. et al.: Image analysis of immunohistochemistry is superior to visual scoring as shown for patient outcome of esophageal adenocarcinoma. Histochem. Cell Biol. 143, 1-9 (2014)
12.
Heindl, S.* et al.: Relevance of MET activation and genetic alterations of KRAS and E-cadherin for cetuximab sensitivity of gastric cancer cell lines. J. Cancer Res. Clin. Oncol. 138, 843-858 (2012)
13.
Kneissl, J.* et al.: Association of amphiregulin with the cetuximab sensitivity of gastric cancer cell lines. Int. J. Oncol. 41, 733-744 (2012)
14.
Luber, B.* et al.: Biomarker analysis of cetuximab plus oxaliplatin/leucovorin/5-fluorouracil in first-line metastatic gastric and oesophago-gastric junction cancer: Results from a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie (AIO). BMC Cancer 11:509 (2011)
15.
Mutze, K.* et al.: Histone deacetylase (HDAC) 1 and 2 expression and chemotherapy in gastric cancer. Ann. Surg. Oncol. 17, 3336-3343 (2010)
16.
Deplazes, J.* et al.: Rac1 and Rho contribute to the migratory and invasive phenotype associated with somatic E-cadherin mutation. Hum. Mol. Genet. 18, 3632-3644 (2009)
17.
Aubele, M. et al.: Prognostic value of protein tyrosine kinase 6 (PTK6) for long-term survival of breast cancer patients. Br. J. Cancer 99, 1089-1095 (2008)
18.
Bremm, A.* et al.: Enhanced activation of epidermal growth factor receptor caused by tumor-derived E-cadherin mutations. Cancer Res. 68, 707-714 (2008)
19.
Fuchs, M.* et al.: Deletion of exon 8 increases cisplatin-induced E-cadherin cleavage. Exp. Cell Res. 314, 153-163 (2008)
20.
Walch, A.K. et al.: Combined analysis of Rac1, IQGAP1, Tiam1 and E-cadherin expression in gastric cancer. Mod. Pathol. 21, 544-552 (2008)